Advance Search
Volume 30 Issue 10
Oct.  2014
Turn off MathJax
Article Contents

doi: 10.11847/zgggws2014-30-10-39
  • Received Date: 2013-07-15
  • Publish Date: 2014-10-10
  • loading
  • [1]
    Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
    [2]
    Cui Z,Yin Z,Li X,et al.Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer:a meta-analysis[J].BMC Cancer,2012,12:71-82.
    [3]
    Butkiewicz D,Rusin M,Sikora B,et al.An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer[J].Mol Biol Rep,2011,38(8):5231-5241.
    [4]
    Kim M,Kang HG,Lee SY,et al.Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer[J].Cancer Sci,2010,101(11):2436-2442.
    [5]
    Wu W,Li H,Wang H,et al.Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients[J].PLoS One,2012,7(3):e33200.
    [6]
    Sun Z,Chen J,Aakre J,et al.Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients[J].Ann Oncol,2010,21(10):2011-2016.
    [7]
    Brundage MD,Davies D,Mackillop WJ.Prognostic factors in non-small cell lung cancer:a decade of progress[J].Chest,2002,3(122):1037-1057.
    [8]
    Hoeijmakers JH.Genome maintenance mechanisms for preventing cancer[J].Nature,2001,411(6835):366-374.
    [9]
    高坚瑞.DNA损伤修复能力与肺癌易感性研究[J].中国公共卫生,2000,16(5):478-479.
    [10]
    唐春兰,杨和平,周向东.DNA损伤修复与肺癌顺铂耐药机制的研究进展[J].中国肺癌杂志,2011,14(12):960-964.
    [11]
    吕嘉春,吴中亮,施侣元,等.核苷酸切除修复基因表达低下与肺癌的关系[J].中国公共卫生,2003,19(7):780-782.
    [12]
    Yin Z,Zhou B,He Q,et al.Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma[J].BMC Cancer,2009,9(12):439-445.
    [13]
    Madhusudan S,Middleton MR.The emerging role of DNA repair proteins as predictive,prognostic and therapeutic targets in cancer[J].Cancer Treat Rev,2005,31(8):603-617.
    [14]
    Matullo G,Dunning AM,Guarrera S,et al.DNA repair polymorphisms and cancer risk in non-smokers in a cohort study[J].Carcinogenesis,2006,27(5):997-1007.
    [15]
    Vilmar A,Sorensen JB.Excision repair cross-complementation group 1(ERCC1)in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin:a review of current literature[J].Lung Cancer,2009,64(2):131-139.
    [16]
    Taillade L,Penault-Llorca F,Boulet T,et al.Immunohistochemical expression of biomarkers:a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer[J].Ann Oncol,2007,18(6):1043-1050.
    [17]
    Takenaka T,Yoshino I,Kouso H,et al.Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer[J].Int J Cancer,2007,121(4):895-900.
    [18]
    Ding Z,Zhang J,Shao J.ERCC1 expression as a predictor of survival after operation in stage I non-small cell lung cancer patients[J].Zhongguo Fei Ai Za Zhi,2010,13(5):522-525.
    [19]
    Olaussen KA,Dunant A,Fouret P,et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].N Engl J Med,2006,335(10):983-991.
    [20]
    Zheng Z,Chen T,Li X,et al.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer[J].N Engl J Med,2007,356(8):800-808.
    [21]
    Takenaka T,Yano T,Kiyohara C,et al.Effects of excision repair cross-complementation group 1(ERCC1)single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients[J].Lung Cancer,2010,67(1):101-107.
    [22]
    Isla D,Sarries C,Rosell R,et al.Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer[J].Ann Oncol,2004,15(8):1194-1203.
    [23]
    Ren S,Zhou S,Wu F,et al.Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy[J].Lung Cancer,2012,75(1):102-109.
    [24]
    Krawczyk P,Wojas-Krawczyk K,Mlak R,et al.Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer-a pilot study[J].Folia Histochem Cytobiol,2012,50(1):80-86.
    [25]
    de Las PR,Sanchez-Ronco M,Alberola V,et al.Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients[J].Ann Oncol,2006,17(4):668-675.
    [26]
    Yin M,Yan J,Voutsina A,et al.No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer:a meta-analysis[J].Lung Cancer,2011,72(3):370-377.
    [27]
    Gurubhagavatula S,Liu G,Park S,et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy[J].J Clin Oncol,2004,22(13):2594-2601.
    [28]
    Booton R,Ward T,Heighway J,et al.Xeroderma pigmentosum group D haplotype predicts for response,survival,and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer[J].Cancer,2006,106(11):2421-2427.
    [29]
    Tibaldi C,Giovannetti E,Vasile E,et al.Correlation of CDA,ERCC1,and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2008,14(6):1797-803.
    [30]
    Wu X,Zhao H,Wei Q,et al.XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity[J].Carcinogenesis,2003,24(3):505-509.
    [31]
    Feng J,Sun X,Sun N,et al.XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer[J].Acta Biochim Biophys Sin(Shanghai),2009,41(5):429-435.
    [32]
    Bernardes DJB,Bjoras M,Coin F,et al.Dissection of the molecular defects caused by pathogenic mutations in the DNA repair factor XPC[J].Mol Cell Biol,2008,28(23):7225-7235.
    [33]
    洪晓华.XPA、XPC和XRCC1基因多态性与非小细胞肺癌铂类化疗患者预后的关系[J].武汉:华中科技大学硕士学位论文,2011.
    [34]
    Kiyohara C,Takayama K,Nakanishi Y.Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk:a meta-analysis[J].Lung Cancer,2006,54(3):267-283.
    [35]
    Schneider J,Classen V,Helmig S.XRCC1 polymorphism and lung cancer risk[J].Expert Rev Mol Diagn,2008,8(6):761-780.
    [36]
    Yao CY,Huang XE,Li C,et al.Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers[J].Asian Pac J Cancer Prev,2009,10(5):859-864.
    [37]
    Lockett KL,Hall MC,Xu J,et al.The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function[J].Cancer Res,2004,64(17):6344-6348.
    [38]
    Zhang X,Miao X,Liang G,et al.Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer[J].Cancer Res,2005,65(3):722-726.
    [39]
    Sanyal S,De Verdier PJ,Steineck G,et al.Polymorphisms in XPD,XPC and the risk of death in patients with urinary bladder neoplasms[J].Acta Oncol,2007,46(1):31-41.
    [40]
    Butkiewicz D,Rusin M,Enewold L,et al.Genetic polymorphisms in DNA repair genes and risk of lung cancer[J].Carcinogenesis,2001,22(4):593-597.
    [41]
    Matullo G,Palli D,Peluso M,et al.XRCC1,XRCC3,XPD gene poly-morphisms,smoking and(32)P-DNA adducts in a sample of healthy subjects[J].Carcinogenesis,2001,22(9):1437-1445.
    [42]
    Au WW,Salama SA,Sierra-Torres CH.Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays[J].Environ Health Perspect,2003,111(15):1843-1850.
    [43]
    Improta G,Sgambato A,Bianchino G,et al.Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer:a case-control study in a Southern Italian population[J].Anticancer Res,2008,28(5B):2941-2946.
    [44]
    Hsu NY,Wang HC,Wang CH,et al.Lung cancer susceptibility and genetic polymorphism of DNA repair gene XRCC4 in Taiwan[J].Cancer Biomark,2009,5(4):159-165.
    [45]
    Shao N,Jiang WY,Qiao D,et al.An updated meta-analysis of XRCC4 polymorphisms and cancer risk based on 31 case-control studies[J].Cancer Biomark,2012,12(1):37-47.
    [46]
    Xu JL,Hu LM,Huang MD,et al.Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese[J].Asian Pac J Cancer Prev,2012,13(3):851-856.
    [47]
    Rosell R,Skrzypski M,Jassem E,et al.BRCA1:a novel prognostic factor in resected non-small-cell lung cancer[J].PLoS One,2007,11(2):e1129.
    [48]
    Taron M,Rosell R,Felip E,et al.BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer[J].Hum Mol Genet,2004,20(13):2443-2449.
    [49]
    Hsu HS,Wen CK,Tang YA,et al.Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer[J].Clin Cancer Res,2005,15(11):5410-5416.
    [50]
    Cheng H,Sun N,Sun X,et al.Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients[J].Acta Biochim Biophys Sin(Shanghai),2010,42(5):311-317.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Article views (992) PDF downloads(35) Cited by()
    Proportional views
    Publishing history
    • Receive:  2013-07-15
    • Published:  2014-10-10

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return